| 1. |
- Suttrop, W., et al.
(författare)
-
In-vessel saddle coils for MHD control in ASDEX Upgrade
- 2009
-
Ingår i: Fusion engineering and design. - Lausanne : ELSEVIER SCIENCE SA. - 0920-3796 .- 1873-7196. ; 84:2-6, s. 290-294
-
Tidskriftsartikel (refereegranskat)abstract
- A set of 24 in-vessel saddle coils is planned for MHD control experiments in ASDEX Upgrade. These coils can produce static and alternating error fields for suppression of Edge Localised Modes, locked mode rotation control and, together with additional conducting wall elements, resistive wall mode excitation and feedback stabilisation experiments. All of these applications address critical physics issues for the operation of ITER. This extension is implemented in several stages, starting with two poloidally separated rings of eight toroidally distributed saddle coils above and below the outer midplane. In stages 2 and 3, eight midplane coils around the large vessel access ports and 12 AC Power converters are added, respectively. Finally (stage 4), the existing passive stabilising loop (PSL), a passive conductor for vertical growth rate reduction, will be complemented by wall elements that allow helical Current patterns to reduce the RWM growth rate for active control within the accessible bandwidth. The system is capable of producing error fields with toroidal mode number n = 4 for plasma edge ergodisation with core island width well below the neo-classical tearing mode seed island width even without rotational shielding. Phase variation between the three toroidal coil rings allows to create or avoid resonances with the plasma safety factor profile, in order to test the importance of resonances for ELM suppression.
|
|
| 2. |
- Wilking, N., et al.
(författare)
-
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
- 2007
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 18:4, s. 694-700
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below theage of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb group, respectively [P = 0.074, hazard ratio (HR) 0.804, 95% confidence interval (CI) 0.633-1.022]. Ten patients in the tailored FEC regimen developed acute myeloid leukaemia (AML)/myelodysplasia (MDS). One hundred deaths occurred in the tailored FEC group and 121 in the CTCb group (P = 0.287, HR 0.866, 95% CI 0.665-1.129). Conclusion: The update of this study shows an improved outcome linked to the tailored FEC treatment in relation to breast cancer relapse, but also an increased incidence of AML/MDS. © 2007 Oxford University Press.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
